免疫状态对Fv—4基因抗Friend MuLV作用的影响

通过检测免疫抑制的Ｆ１小鼠和杂合子Ｆ２裸鼠对Ｆｒｉｅｎｄ小鼠白血病病毒（Ｆｒ．ＭｕＬＶ）感染的敏感性,探讨免疫状态对Ｆｖ－４基因（特别是对Ｆｖ－４基因杂合子）抗ＦｒｉｅｎｄＭｕＬＶ作用的影响,经腹腔接种Ｆｒ．ＭｕＬＶ病毒液攻击小鼠或Ｆ２裸鼠后,检查其计中Ｆｒ．ＭｕＬＶ的增主其发病情况,结果表明,免疫抑制的Ｆ１小鼠和杂合子Ｆ１裸鼠都可被Ｆｒ．ＭｕＬＶ脾脏中有病毒增殖,并用约２／３的杂合子Ｆ２裸鼠与Ｂ     

氯化甲基汞对大鼠脑神经细胞凋亡及P^53基因表达的影响

选用Ｗｉｓｔａｒ系雄性大鼠,经皮下注射给予１０ｍｇ／Ｋｇ体重氯化甲基汞（ＣＨ３ＨｇＣｌ）,连续７天,第１５天取其脑组织,利用细胞和分子生物学技术进行ＤＮＡ电泳和流式细胞术（ＦＣＭ）分析。实验结果,染毒组大鼠脑组织ＤＮＡ电泳呈现特征性梯形电泳带;ＦＣＭ分析染毒组大鼠脑神经细胞的凋亡率、Ｐ５３基因表达率显著高于对照组（Ｐ＜０．０５）。结果表明：ＣＨ３ＨｇＣｌ以诱导凋亡方式导致脑神经细胞损伤,Ｐ５３基因参与ＣＨ３ＨｇＣｌ诱导脑神经细胞凋亡的基因调控过程。     

采用定点基因缺失突变技术在大肠杆菌中分泌鲑鱼生长激素

目的：为获得与天然鲑鱼生长激素一致的基因工程产物,对已构建的鲑鱼生长激素基因分泌型表达质粒ｐＯｓＧＨ１５３进行改造,删除所编码表达产物氨基端多余的９个碱基,方法：采用ＰＡＬＴＥＲ系统进行寡聚核苷酸指导下的基因定点缺失突变。突变质粒ｐＯｓＧＨ１５８经限制性酶切图谱及Ｓｏｕｔｈｅｒｎ印迹杂交分析加以证,结果：含有表达质粒ｐＯｓＧＨ１５８的大肠杆菌株经ＩＰＴＧ诱导后提取周质帽白,经ＳＤＳ－ＰＡＧＥ及免疫     

反义胰岛素样生长因子—1mRNA治疗大鼠脑胶质瘤模型的动态MR研究

目的：动态观察大鼠Ｃ６胶质瘤模型的自然生长过程及反义ＩＧＦ－１ｍＲＮＡ对胶质瘤的治疗效果和治疗机制。方法：将３２只Ｗｉｓｔａｒ大鼠分成４组,每组８只,（１）对照组（Ｃ组）于右尾状核接种Ｃ６鼠胶质瘤细胞。（２）治疗组（Ｔ组）：于右尾状核接种Ｃ６细胞后的第７、１０天在接种点注射脂质体包裹的质粒Ｐ－ａｎｔｉ－ＩＧＦ－１,对胶质瘤进行治疗于右尾状核接种经反义ＩＧＦ－１ｍＲＮＡ转染的Ｃ６胶质瘤细胞。（４）Ｋ     

Molecular-pathological Analysis of a Patient with Three Synchronous Squamous Cell Carcinomas in the Aerodigestive Tract

A case of synchronous squamous cell carcinomas in the soft palate,larynx and esophagus is reported, along with findings of molecular-pathologicalanalysis. A biopsy sample from the aryngeal carcinoma revealedwell differentiated squamous cell carcinoma harboring two pointmutations at codons 144 and 148 of the p53 gene but not at codon299, and more than 50% of the cancer cells showed accumulationof p53 protein immunohistochemically. The esophageal tumor,which was moderately differentiated squamous cell carcinoma,showed immunoreactivity for p53 within the nuclei of 25–50%of cancer cells with a missense mutation at codon 299 but notat codon 144 or 148. This cancer also showed immunoreactivityfor transforming growth factor alpha. On the other hand, thepoorly differentiated squamous cell carcinoma in the soft palateshowed negative immunoreactivity for p53 and no point mutationin exons 5 to 8 of the gene. These results suggest that thethree synchronous squamous cell carcinomas arose as independentevents.     

Breast cancer angiogenesis — new approaches to therapy via antiangiogenesis,hypoxic activated drugs,and vascular targeting

Summary Several groups have shown that quantitation of tumor angiogenesis by counting blood vessels in primary breast cancer gives an independent assessment of prognosis. Poor prognosis is associated with high blood vessel counts. We have shown that the rate of cell division in endothelial cells is much higher in breast tumours than in normal breast. Breast cancer cell lines and primary human breast tumours express a wide range of vascular growth factors, including VEGF, placenta growth factor, pleiotrophin, TGF1, acidic and basic FGF, and platelet-derived endothelial cell growth factor. Inhibiting angiogenesis by blocking vascular growth factors would be difficult with highly specific agents, but drugs with a broader spectrum of antagonism may be effective. We have developed several suramin analogues which are less toxic than suraminin vivo but more potent in inhibiting angiogenesis, and these have been developed for Phase I. A combination of anti-angiogenesis agents with drugs activated by hypoxia may also be useful, because anti-angiogenesis alone may not kill cells, whereas activation of hypoxic drugs could synergize.New endpoints may be necessary because inhibition of new blood vessel formation may not cause tumour regression. Thus, the endpoint of stable disease and biochemical assessment of inhibition of angiogenesis may be much more important in therapeutic studies and for drug development in the future. The prognostic importance of angiogenesis suggests that this should be a major new therapeutic target.Presented at the symposium "New Approaches in the Therapy of Breast Cancer", Georgetown University Medical Center, Washington DC, October 1994, generously supported by an education grant from Bristol-Myers Squibb.     

Amplifications of oncogeneerbB-2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction

Summary A new method of measuring gene copy number in small samples of DNA was used to measure amplification of theerbB-2 gene and of chromosome 20q in breast cancers. This method, termed differentially competitive polymerase chain reaction (DC-PCR) combines the advantages of two other techniques for measuring amplification by PCR, namely differential PCR and competitive PCR. The DC-PCR methodology was evaluated for sensitivity and specificity by comparing amplification oferbB-2 measured by DC-PCR with that obtained by fluorescencein situ hybridization (FISH) for 42 cases or Southern blotting and/or slot blot analysis for 34 cases. There was over 90 percent concordance with both FISH and Southern blotting and/or slot blot analysis.DC-PCR was used to further characterize the newly described amplicon at chromosome 20q. By analyzing DNA from 10 breast cancer cell lines at 7 different loci, we identified a potential common region of amplification of approximately 5 centimorgans at chromosome 20q13 bordered by loci D20S52 and RMC20C001-S1. One hundred and seventeen cases of primary breast cancer were evaluated for amplification at these two loci. Amplification at one or more loci, defined as > 1.5 fold higher copy number than that of normal DNA, was found in 25 cases (21%). Sixteen cases were amplified at only one of the two probes (12 cases for RMC20C001-S1 and 4 cases for D20S52), suggesting that the target gene lies between the two markers or that there are two independent target genes within a small chromosome region.     

nm23-H1 expression in squamous cell carcinoma of the head and neck

Archival material from 47 patients with primary squamous cell carcinoma of the head and neck (SCCHN) was studied immunohistochemically for the presence of nm23-H1 protein. Our data indicate that nm23-H1 protein expression is a common event in SCCHN and that there is a trend toward correlation of increased expression of nm23-H1 with increasing tumor size (p = 0.072). The results also show that when adjusting for age and cause of death, there tended to be an inverse relationship between overall survival and the expression of nm23-H1 gene in the primary tumor (p = 0.088).     

腺病毒介导的p53基因对喉癌细胞生长的抑制作用

目的探索ｐ５３基因在喉癌基因治疗方面的可行性。方法以人喉癌细胞系Ｈｅｐ－２为实验对象,将载有人野生型ｐ５３ｃＤＮＡ并含巨细胞病毒（ＣＭＶ）启动子的重组腺病毒（Ａｄ５ＣＭＶ－ｐ５３）感染Ｈｅｐ－２细胞及肿瘤组织,体内外实验观察Ａｄ５ＣＭＶ－ｐ５３对Ｈｅｐ－２细胞生长的影响。结果当Ａｄ５ＣＭＶ－ｐ５３在１００ＭＯＩ效靶比时,全部Ｈｅｐ－２细胞得到转染。感染２天后ｐ５３蛋白表达达到高峰,Ｈｅｐ－２生长受到明显的抑制。Ａｄ５ＣＭＶ－ｐ５３感染Ｈｅｐ－２细胞在裸鼠中失去致瘤性。瘤内注射Ａｄ５ＣＭＶ－ｐ５３后,荷瘤裸鼠的肿瘤体积明显减小。结论Ａｄ５ＣＭＶ－ｐ５３转导野生型ｐ５３基因可能是一种有效的喉癌基因治疗途径。